[Treatment of patients with chronic hepatitis C who have not been previously treated].
Marcellin
Patrick
P
Service d'Hépatologie, INSERM U 481 et Centre Claude-Bernard sur les Hépatites Virales, Hôpital Beaujon, Clichy.
Boyer
Nathalie
N
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011092:Polyethylene Glycols; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
D000998:Antiviral Agents; D016898:Interferon-alpha; D010919:Placebos; D012367:RNA, Viral; D011092:Polyethylene Glycols; D012254:Ribavirin